NCT02557945

Gabapentin in Patients at Clinical Risk for Psychosis

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.

Detailed description

Six week, single site, proof-of concept, randomized double-blind placebo-controlled pilot study to examine the effects of moderate dose gabapentin (3600mg) in n= 100 putatively prodromal patients on hippocampal activity.

Conditions

• Clinical High Risk for Psychosis

Interventions

Type	Name	Description
DRUG	Gabapentin	Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
DRUG	Placebo	Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)

Timeline

• Start date: 2015-08-01
• Primary completion: 2016-06-12
• Completion: 2016-06-12
• First posted: 2015-09-23
• Last updated: 2022-05-03
• Results posted: 2022-05-03

Locations

1 site across 1 country: United States